Literature DB >> 10943681

R-(+)-verapamil, S-(-)-verapamil, and racemic verapamil inhibit human retinal pigment epithelial cell contraction.

F Faude1, V Enzmann, E Pöschmann, S Hoffmann, P Wiedemann.   

Abstract

PURPOSE: To evaluate the effects of R-(+)-verapamil, S-(-)-verapamil, and the racemate on in vitro contraction of human retinal pigment epithelial cells.
METHODS: RPE cells from human donor eyes were enzymatically dissociated and cultured on collagen gels. Transdifferentiated RPE cells (seventh and eighth passage) were used for experiments. The contraction assays were treated with different concentrations (10-1000 microM) of R-(+)-verapamil, S-(-)-verapamil, and racemic verapamil.
RESULTS: Verapamil inhibited the gel contraction of human RPE cells. R-(+)-verapamil, S-(-)-verapamil, and racemic verapamil acted equally in a dose-dependent manner from 10-1000 microM.
CONCLUSION: The results indicate the effectiveness of verapamil to inhibit the contraction of RPE cells. R-(+)-verapamil is recommended because it is associated with fewer systemic and local side effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943681     DOI: 10.1007/pl00007897

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  2 in total

1.  Inhibitory effects of verapamil isomers on the proliferation of choroidal endothelial cells.

Authors:  Stephan Hoffmann; Stephanie Balthasar; Ulrike Friedrichs; Marianne Ehren; Stephen J Ryan; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-09       Impact factor: 3.117

2.  Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by the human lectin galectin-1.

Authors:  Claudia S Alge-Priglinger; Sabine André; Thomas C Kreutzer; Cornelia A Deeg; Anselm Kampik; Marcus Kernt; Harald Schöffl; Siegfried G Priglinger; Hans-Joachim Gabius
Journal:  Mol Vis       Date:  2009-10-23       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.